)

Minerva Neurosciences (NERV) investor relations material
Minerva Neurosciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Focused on proprietary CNS therapies, with lead candidate roluperidone for schizophrenia and MIN-301 for Parkinson's disease; no commercialized products or revenue to date.
FDA issued a Complete Response Letter for roluperidone, requiring a new 52-week confirmatory trial before resubmission, impacting regulatory timelines.
Strategic alternatives are under review due to cash constraints and regulatory requirements.
Accumulated deficit reached $402.4 million as of June 30, 2025; net loss for the six months ended June 30, 2025 was $7.0 million, improved from $16.8 million year-over-year.
Financial highlights
Cash, cash equivalents, and restricted cash totaled $15.3 million as of June 30, 2025, down from $21.5 million at year-end 2024.
Net loss for Q2 2025 was $3.3 million ($0.43/share), improved from $6.3 million ($1.09/share) in Q2 2024.
Research and development expenses decreased to $1.3 million in Q2 2025 from $3.9 million in Q2 2024; six-month R&D was $2.7 million vs $8.0 million prior year.
General and administrative expenses fell to $2.1 million in Q2 2025 from $2.4 million in Q2 2024; six-month G&A was $4.6 million vs $4.9 million prior year.
No revenue generated from product sales or licenses; all income derived from investment and royalty arrangements.
Outlook and guidance
Existing cash is not sufficient to fund operations and capital requirements beyond the next twelve months; cost reduction initiatives are underway.
Additional capital will be required to advance clinical programs and support operations; strategic alternatives, including partnerships or transactions, are under review.
Uncertainty remains regarding the timing and outcome of the required confirmatory trial for roluperidone and future regulatory approvals.
Next Minerva Neurosciences earnings date

Next Minerva Neurosciences earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage